血小板因子4(PF4)活性蛋白
Active Platelet Factor 4 (PF4)
CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact
- 編號APA172Mu01
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)9.4
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 883 ¥ 2208 ¥ 4416 ¥ 13248 ¥ 33120
- 欲了解實(shí)際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)
Platelet factor 4 (PF4) is a small cytokine belonging to the CXC chemokine family that is also known as chemokine (C-X-C motif) ligand 4 (CXCL4). This chemokine is released from alpha-granules of activated platelets during platelet aggregation, and promotes blood coagulation by moderating the effects of heparin-like molecules. Due to these roles, it is predicted to play a role in wound repair and inflammation. To measure its ability to inhibit the FGF basic-dependent proliferation of HUVEC human umbilical vein endothelial cells, HUVEC cells were seeded into 96-well plates at a density of 3,000 cells/well with 2% serum standard DMEM including 1μg/mL recombinant human FGF1 and various concentrations of recombinant human PF4. After incubated for 48h,?cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10μL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-2 hours at 37℃. Proliferation of HUVEC cells after incubation with PF4 for 48h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinant human PF4 for 48h. The result was shown in Figure 2. It was obvious that PF4 significantly FGF basic-dependent proliferation of HUVEC cells. The ED50 is 3.4μg/mL.
(A)HUVEC cells cultured in DMEM with 1μg/mL FGF1, stimulated with 5μg/mL PF4 for 48h;
(B) Unstimulated HUVEC cells cultured in DMEM with 1μg/mL FGF1 for 48h.
Figure. Inhibition of HUVEC cells proliferation after stimulated with PF4.
Figure. Inhibition of FGF basic-dependent HUVEC proliferation after stimulated with PF4.
用法
Reconstitute in 20mM Tris, 150mM NaCl (PH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA172Mu01 | 血小板因子4(PF4)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA172Mu01 | 血小板因子4(PF4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA172Mu02 | 血小板因子4(PF4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA172Mu01 | 血小板因子4(PF4)多克隆抗體 | WB; IHC; ICC; IP. |
PAA172Mu02 | 血小板因子4(PF4)多克隆抗體 | WB; IHC; ICC; IP. |
LAA172Mu71 | 血小板因子4(PF4)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
LAA172Mu81 | 血小板因子4(PF4)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
SEA172Mu | 血小板因子4(PF4)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA172Mu | 血小板因子4(PF4)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA172Mu | 血小板因子4(PF4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA172Mu01 | 血小板因子4(PF4)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats [PubMed: 20601223] |
Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation [PubMed: 22899170] |
PLoS One | Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation [PubMed: PMC3608633] |
Diving and Hyperbaric Medicine | Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression [Pubmed:25311322] |
Journal of Functional Foods | A?Phellinus baumii–based supplement containing?Salvia miltiorrhiza?Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro?and?in vivo [science:S1756464616300676] |
Plos one | Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury [pubmed:27583400] |
international journal of molecular sciences | Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation. [pubmed:28272338] |
Experimental?and?Therapeutic?Medicine | Feasibility of improving platelet?rich plasma therapy by using chitosan with high platelet activation ability [pubmed:28450960] |
Reproductive Toxicology | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats [Pubmed: 30528429] |
INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation [Pubmed: 30857843] |
Available at SSRN 3335365? | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers [] |
journal of biotechnology | Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes Hemostasis [Pubmed: 30927490] |
Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation [] |
journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers [Pubmed: 32812629] |
Marine Drugs | The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents [Pubmed: 31533230] |
Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices [Pubmed: 31838449] |
Nat Commun | The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets [34099640] |
Vaccine | The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats [Pubmed:35183388] |